Eli Lilly drug slows Alzheimer’s disease, study finds
Slowing the disease by 35% over one and a half years paves the way for the US-based drugmaker to seek approval.
By Robert Langreth & Nacha Cattan, bloomberg
Eli Lilly & Co.’s shares climbed in premarket trading after its experimental drug for Alzheimer’s slowed the progress of the disease in a final-stage trial, paving the way for the company to apply for US approval.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Eli Lilly Alzheimer’s drug fails to prevent disease in trial
For subscribers
